ICER says AstraZeneca’s new blood pressure med isn’t cost-effective
The drug price watchdog ICER issued a report Thursday concluding that the benefits of AstraZeneca’s new blood pressure pill Baxfendy don’t justify its $10,950 per year price tag. Baxfendy is forecast to be a major ...
August 14, 2026 11:15 AM EDT Pharma ICER says AstraZeneca’s new blood pressure med isn’t cost-effective Elizabeth Cairns Senior biopharma journalist The drug price watchdog ICER issued a report Thursday concluding that the benefits of AstraZeneca’s new blood pressure pill Baxfendy don’t justify its $10,950 per … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that